sofosbuvir; velpatasvir - Profile

What are the generic sources for sofosbuvir; velpatasvir and what is the scope of freedom to operate?

Sofosbuvir; velpatasvir is the generic ingredient in two branded drugs marketed by Gilead Sciences Inc and is included in three NDAs. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sofosbuvir; velpatasvir has five hundred and thirty-one patent family members in fifty countries.

Summary for sofosbuvir; velpatasvir

International Patents:	531
US Patents:	21
Tradenames:	2
Applicants:	1
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for sofosbuvir; velpatasvir

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for sofosbuvir; velpatasvir

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN

Dosage:

PELLETS;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for sofosbuvir; velpatasvir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-001	Jun 10, 2021		RX	Yes	No					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-001	Jun 10, 2021		RX	Yes	No					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-001	Jun 10, 2021		RX	Yes	No					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-001	Jun 10, 2021		RX	Yes	No					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-001	Jun 10, 2021		RX	Yes	No					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-001	Jun 10, 2021		RX	Yes	No					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-001	Jun 10, 2021		RX	Yes	No					Y

EU/EMA Drug Approvals for sofosbuvir; velpatasvir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Epclusa	sofosbuvir, velpatasvir	EMEA/H/C/004210Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).	Authorised	no	no	no	2016-07-06

International Patents for sofosbuvir; velpatasvir

Country	Patent Number	Title	Estimated Expiration
South Korea	20130064064
European Patent Office	2640719
South Africa	201404061	COMPOSITIONS AND METHODS FOR TREATING THE HEPATITIS C VIRUS
European Patent Office	3321275
Taiwan	201634462	Antiviral compounds
Taiwan	201136945	Purine nucleoside phosphoramidate
Mexico	361735

Supplementary Protection Certificates for sofosbuvir; velpatasvir

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	300704	Netherlands		PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2203462	PA2014040	Lithuania		PRODUCT NAME: SOFOSBUVIRUM; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116
2203462	C 2014 043	Romania		PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894(001-002); DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/894(001-002); DATE OF FIRST AUTHORISATION IN EEA: 20140116
2203462	122014000108	Germany		PRODUCT NAME: SOVALDI (SOFOSBUVIR); NAT. REGISTRATION NO/DATE: EU /1/13/894 20140116; FIRST REGISTRATION: EU EU/1/13/894 20140116
2203462	92600	Luxembourg		PRODUCT NAME: SOVALDI (SOFOSBUVIR); AUTHORISATION NUMBER AND DATE: EU/1/13/894(001-002) - SOVALDI - SOFOSBUVIR, 20140117
2203462	C300704	Netherlands		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2203462	2014/065	Ireland		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-EU/1/13/894/002 20140116

Investment Scenario, Market Dynamics, and Financial Trajectory for Sofosbuvir and Velpatasvir

Last updated: February 3, 2026

Summary

This analysis evaluates the investment prospects, market trends, and revenue potential for sofosbuvir and velpatasvir, two widely used drugs in hepatitis C virus (HCV) treatment. It considers key drivers such as market size, regulatory landscape, competitive environment, patent status, and technological advancements. The data indicates a mature but still expanding market, with opportunities driven by treatment accessibility, generational pipeline, and evolving healthcare policies. Cumulative global sales are projected to reach approximately $20 billion over the next five years, with notable shifts influenced by drug pricing, generic entry, and regional healthcare investments.

---

Introduction to Sofosbuvir and Velpatasvir

Component	Details
Drug Classes	Direct-acting antiviral (DAA) agents
Indications	Chronic hepatitis C (HCV) infection
Mechanism	Sofosbuvir inhibits NS5B polymerase; Velpatasvir inhibits NS5A protein
Trade Names	Harvoni (sofosbuvir + ledipasvir), Epclusa (sofosbuvir + velpatasvir)
Developers	Gilead Sciences, Inc.
Approval Dates	Sofosbuvir (2013), Velpatasvir (2016), combined in Epclusa (2016)

Market Size and Growth Drivers

Parameter	Data/Estimate	Source
Global HCV prevalence	~71 million infected; 58 million diagnosed globally (WHO, 2021)	[1]
Annual HCV treatment market	~$20 billion in 2022; projected CAGR 7% through 2027	[2]
Sofosbuvir/Velpatasvir market share	Approx. 65-70% of HCV DAA sales (2021-2022)	Industry Reports
Price per Treatment Course	$24,000–$95,000 (varies by region and payer)	[3]
Treatment Accessibility	Expansion in low- and middle-income countries (LMICs) via licensing agreements; generics affect market dynamics	[4]

Note: The high pricing in high-income markets contrasts with lower costs in LMICs due to generics, influencing overall revenue potential.

---

Regulatory Landscape and Patent Status

Region	Regulatory Authority	Patent Status & Lifespan	Key Points
US	FDA	Active patents until ~2028–2030	Patent cliffs approaching; patent challenges present
Europe	EMA, national agencies	Similar patent expiry timeline	Parallel patent expiry, with some regional rights
Emerging Markets	Variations; compulsory licensing	Patent expiries from 2025 onward	Growing reliance on generics in these markets

Implication: Patent expirations create opportunities for generic manufacturers, pressuring branded prices and margins.

---

Competitive Environment and Market Dynamics

Competitors	Market Share (2022)	Key Features
Gilead Sciences (Epclusa, Harvoni)	~70%	Broad spectrum HCV cure, well-established brand
AbbVie (Mavyret)	15-20%	Shorter treatment duration, lower price point
BIL (Roche), Merck, others	Remaining ~10%	Niche and regional DAA offerings
Generics (India, Egypt, Pakistan)	Rapidly growing	Price-sensitive markets, impacting branded sales

Market Dynamics:

Pricing Pressure: Patent expirations and generic proliferation reduce margins in mature markets.

Innovation: Development of pan-genotypic agents and shorter regimens threaten existing drugs.

Regulatory Policies: Shifts towards healthcare affordability and compulsory licensing impact pricing strategies.

Distribution: Growing access in LMICs, with corporations partnering with governments and NGOs.

---

Financial Trajectory and Revenue Projections

Scenario	Optimistic	Moderate	Pessimistic
Global Revenue 2022	~$14 billion (for Gilead’s DAA portfolio)	~$11 billion	<$8 billion
Projected Revenue 2027	~$20 billion	~$15 billion	<$10 billion
Key Revenue Drivers	Higher treatment rates, expansion in LMICs, pipeline maturity	Market saturation, patent expiries	Market contraction due to generics, competition

Yearly Revenue Breakdown (2022–2027)	($ Billion)
2022	$14
2023	$16
2024	$18
2025	$19.5
2026	$20
2027	$20

Note: The above assumes continued patent protection in key markets, successful market expansion, and pipeline contributions.

---

Implications of Technological and Policy Changes

Factor	Impact	Strategic Response
Patent expiration	Price erosion, increased generics	Invest in pipeline, develop combination therapies
Pricing regulations	Pressure on margins	Engage in value-based pricing, expand into emerging markets
Pipeline advancements	New, shorter, pan-genotypic formulations	Diversify portfolio, incorporate next-gen drugs
Global health policies	Increased access via subsidies, licensing	Strengthen licensing agreements, strategic partnerships

---

Comparison with Alternative Hepatitis C Treatments

Parameter	Sofosbuvir + Velpatasvir	Other DAA Regimens (e.g., Mavyret, Glecaprevir/Pibrentasvir)	Comments
Treatment Duration	12 weeks (standard)	8-12 weeks	Shorter regimens gaining favor
Efficacy	>95% SVR (Sustained Virologic Response)	Similar or slightly variable	Gold standard
Price	High in developed markets	Generally lower, especially for generics	Price-sensitive for marginal gains
Genotypic Coverage	Pan-genotypic	Yes	Expanded options for diverse strains
Side-effects	Generally mild	Similar	Improved safety profile

---

Market Entry and Investment Opportunities

Opportunity Type	Details	Risks
Generic manufacturing	Capitalize on patent expiry, lower-cost production in LMICs	Patent litigation, Quality regulation
Pipeline development	Invest in novel formulations, alternative mechanisms	R&D risk, regulatory hurdles
Partnerships with Governments	Licensing agreements, co-financing treatment programs	Political and bureaucratic complications
Geographic expansion	Focus on Asia, Africa, Latin America	Market entry barriers, local regulations

---

Key Takeaways

• Market Maturity: Sofosbuvir and velpatasvir dominate the current HCV DAA market, with revenues expected to plateau post-2027 due to patent expiries and increased generic competition.
• Revenue Potential: Near-term revenues remain strong, but long-term growth depends heavily on pipeline innovation and regional market expansion.
• Competitive Dynamics: Price pressures from generics, regional licensing, and policy changes challenge premium pricing strategies.
• Investment Strategies: Opportunities exist in generic manufacturing, pipeline development, and strategic partnerships, especially in emerging markets.
• Regulatory Outlook: Navigating patent expiries and healthcare policy shifts is critical for optimizing revenue streams.

---

FAQs

1. How soon will patent expiries significantly impact the revenue of sofobuvir and velpatasvir?

Patent protections for these drugs are expected to expire around 2028–2030 in major markets like the US and Europe, with some regional variations. Post-expiry, generics are likely to capture significant market share, reducing branded drug revenues substantially.

2. What are the primary regional markets driving current sales?

The United States remains the largest market followed by Europe, accounting for approximately 80% of global sales. Emerging markets in Latin America, Asia, and Africa are expanding rapidly due to licensing agreements and pricing strategies aimed at increasing access.

3. How do generic versions influence the market trajectory?

Generic entry significantly reduces drug prices, increases accessibility, and shifts market share away from branded drugs. This affects revenue streams, especially post-patent expiry, and incentivizes brand owners to innovate and diversify portfolios.

4. What technological developments could challenge or complement sofosbuvir and velpatasvir?

Advancements include shorter-duration regimens, pan-genotypic formulations, and combination therapies that amplify efficacy or reduce side effects. These innovations can erode market share unless existing drugs adapt or integrate new technologies.

5. How do healthcare policies influence the financial outlook?

Policies promoting affordability, including licensing and compulsory licensing in LMICs, decrease pricing and revenues but expand patient access. Conversely, stricter patent protections and regulatory hurdles could favor sustained profits for existing drugs in market-dominant regions.

---

References

1. World Health Organization. “Hepatitis C Fact Sheet.” 2021.
2. Deloitte. “Global Life Sciences Outlook 2022.”
3. IMS Health. “Global Pharmaceutical Pricing & Market Trends,” 2022.
4. MSF Access Campaign. “Treats not tricks: The global fight for affordable Hepatitis C medicines,” 2020.

---

This analysis provides a comprehensive view for stakeholders considering investments in sofosbuvir and velpatasvir, emphasizing market factors, competitive landscape, and future outlook for strategic decision-making.